EP3852724 - CARBETOCIN DRUG PRODUCT AND PROCESS FOR PREPARING SAME [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 17.05.2024 Database last updated on 24.08.2024 | |
Former | Request for examination was made Status updated on 25.06.2021 | ||
Former | The international publication has been made Status updated on 28.03.2020 | Most recent event Tooltip | 23.05.2024 | New entry: Despatch of examination report + time limit | Applicant(s) | For all designated states ACADIA Pharmaceuticals Inc. 12830 El Camino Real, Suite 400 San Diego, CA 92130 / US | [2023/12] |
Former [2021/30] | For all designated states Levo Therapeutics, Inc. 5215 Old Orchard Road, Suite 965 Skokie, IL 60077 / US | Inventor(s) | 01 /
BRYANT, Christopher c/o Levo Therapeutics, Inc. 5215 Old Orchard Road 450 Skokie, Illinois 60077 / US | 02 /
MANNING, Mark C. c/o Levo Therapeutics, Inc. 5215 Old Orchard Road 450 Skokie, Illinois 60077 / US | 03 /
HOLCOMB, Ryan E. c/o Levo Therapeutics, Inc. 5215 Old Orchard Road 450 Skokie, Illinois 60077 / US | [2021/30] | Representative(s) | Maiwald GmbH Grünstraße 25 40212 Düsseldorf / DE | [N/P] |
Former [2021/30] | Cooley (UK) LLP 22 Bishopsgate London EC2N 4BQ / GB | Application number, filing date | 19862482.7 | 20.09.2019 | [2021/30] | WO2019US52092 | Priority number, date | US201862734134P | 20.09.2018 Original published format: US 201862734134 P | US201962876870P | 22.07.2019 Original published format: US 201962876870 P | [2021/30] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020061416 | Date: | 26.03.2020 | Language: | EN | [2020/13] | Type: | A1 Application with search report | No.: | EP3852724 | Date: | 28.07.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 26.03.2020 takes the place of the publication of the European patent application. | [2021/30] | Search report(s) | International search report - published on: | US | 26.03.2020 | (Supplementary) European search report - dispatched on: | EP | 09.06.2022 | Classification | IPC: | A61K9/08, A61K38/095, A61K47/38 | [2022/27] | CPC: |
A61K9/08 (EP,IL,KR,US);
A61K38/095 (EP,IL,KR,US);
A61K47/22 (IL,KR,US);
A61K47/26 (IL,KR,US);
A61K47/38 (EP,IL,KR,US);
A61K9/0043 (KR);
A61P25/00 (KR)
(-)
|
Former IPC [2021/30] | A61K9/08, A61K38/095 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/30] | Title | German: | CARBETOCIN-ARZNEIMITTELPRODUKT UND VERFAHREN ZU SEINER HERSTELLUNG | [2021/30] | English: | CARBETOCIN DRUG PRODUCT AND PROCESS FOR PREPARING SAME | [2021/30] | French: | PRODUIT MÉDICAMENTEUX À LA CARBÉTOCINE ET SON PROCÉDÉ DE PRÉPARATION | [2021/30] | Entry into regional phase | 19.04.2021 | National basic fee paid | 19.04.2021 | Search fee paid | 19.04.2021 | Designation fee(s) paid | 19.04.2021 | Examination fee paid | Examination procedure | 19.04.2021 | Examination requested [2021/30] | 20.12.2022 | Amendment by applicant (claims and/or description) | 22.05.2024 | Despatch of a communication from the examining division (Time limit: M04) | Fees paid | Renewal fee | 22.09.2021 | Renewal fee patent year 03 | 27.09.2022 | Renewal fee patent year 04 | 27.09.2023 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]US2012172304 (LEONARD ALEXIS KAYS [US], et al) [Y] 1-17 * page 8, paragraph 72 * * page 3, paragraphs 19-29 * * pages 12-14, paragraph 114; example 1; table 1 * * page 15; example 2; table 2 * * pages 21-22, paragraph 165; examples 5-6 * * Formulation 7; page 30; table 33 *; | [XY] - HØGSTEDT ULRICH B. ET AL, "Manipulating Aggregation Behavior of the Uncharged Peptide Carbetocin", JOURNAL OF PHARMACEUTICAL SCIENCES, US, vol. 107, no. 3, doi:10.1016/j.xphs.2017.11.008, ISSN 0022-3549, (20171121), pages 838 - 847, URL: https://jpharmsci.org/action/showPdf?pii=S0022-3549(17)30830-4, (20220524), XP055925065 [X] 1,2,7,8,14 * abstract * * page 839, column left, paragraph last - page 839, column right, paragraph 2 * * figure 2 * * table 2 * [Y] 1-17 DOI: http://dx.doi.org/10.1016/j.xphs.2017.11.008 | International search | [A]US2004235956 (QUAY STEVEN C [US]) [A] 1-4, 18-19, 22-26, 28-29, 31-35, 37-39, 42/18-19, 42/22, 43/18-19, 43/22, 44/18-19, 44/22, 45/44/18-19, 45/44/22, 46/18-19, 46/22, 47/18-19, 47/22 * ; abstract; paragraphs [0015], [0020], [0041], [0047], [0081]-[0083] *; | [XY]WO2008042452 (NASTECH PHARM CO [US], et al) [X] 5-9 * ; abstract; page 8, lines 8-10; page 11, lines 10-13; page 16, lines 14-24; page 18, lines 13-19; page 30, lines 10-13; page 41, lines 14-22; page 42, lines 5-12; page 54, table 23; claim 1 * [Y] 10-17; | [A]US2010311655 (LEONARD ALEXIS KAYS [US], et al) [A] 1-4, 18-19, 22-26, 28-29, 31-35, 37-39, 42/18-19, 42/22, 43/18-19, 43/22, 44/18-19, 44/22, 45/44/18-19, 45/44/22, 46/18-19, 46/22, 47/18-19, 47/22* ; paragraphs [0014], [0038], [0049], [0057], [0093] *; | [Y]WO2012042371 (FERRING BV [NL], et al) [Y] 11-13, 15-17 * ; page 5, lines 17-21; page 3, lines 31-33; page 4, lines 4-6; page 5, lines 17-25; page 24, lines 25-36; page 25, lines 1-5 *; | [Y]WO2014107231 (ACIEX THERAPEUTICS INC [US]) [Y] 11-17 * ; paragraph [00382] *; | [X]US2017326200 (DANGLAS PASCAL [CH], et al) [X] 48-49, 50/48-49 * ; paragraphs [0007), [0028], [0030], [0032], [0037], [0044], [0056], [0064]-[0065], [0095]-[0097] *; | [Y]WO2018158234 (DUTCH RENEWABLE ENERGY B V [NL]) [Y] 10-17 * ; abstract * |